Enteric vaccines for the developing world: challenges and prospects
2011

Enteric Vaccines for the Developing World: Challenges and Prospects

publication Evidence: moderate

Author Information

Author(s): Cecil Czerkinsky, Roberto Bruzzone

Primary Institution: International Vaccine Institute

Conclusion

Oral killed whole cholera bacteria vaccine is effective and affordable, providing protection for at least 3 years.

Supporting Evidence

  • The oral killed whole cholera bacteria vaccine has been documented as effective in one of the largest clinical efficacy trials for an enteric vaccine.
  • The cholera vaccine can be produced at industrial scale and is affordable for the poorest populations.
  • The vaccine provides direct and community protection for at least 3 years.
  • A second vaccine against typhoid fever is highly immunogenic in children.
  • A third vaccine targeting Shigella has shown protection in animal models.

Takeaway

Scientists are working on vaccines to help prevent diarrhea in babies and young kids in poor countries, and some vaccines are already showing good results.

Methodology

The study involved extensive research on vaccine candidates, including clinical efficacy trials for an oral cholera vaccine.

Participant Demographics

Children from cholera endemic areas.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication